HEALTH OF WOMAN. 2019.3(139): 81–86; doi 10.15574/HW.2019.139.81

Vdovichenko Yu. P., Gladenko S. E.
Shupyk National Medical Academy of Postgraduate Education, Kiev

Diffuse benign dysplasia of the mammary glands is one of the frequent pathologies that practitioners almost daily encounter. Studying the mechanisms of development of pathological gynecological conditions, the researchers concluded that there is a pathogenetic connection between cyclic changes in the reproductive system and the physiological processes occurring in the mammary glands. This makes it possible to assume a high probability of occurrence of pathological changes in the mammary glands in various gynecological diseases, developing as a result of disorders of the hypothalamic-pituitary-ovarian system. The general inhibition and unity of the reaction of the reproductive organs to hormonal imbalance is the main prerequisite for the development of benign hyperplastic and the risk of malignant processes.

The relevance of studying the reproductive health of patients with dyshormonal non-inflammatory pathology of the genital organs is due to the steady increase in the proportion of this pathology in recent years in the structure of gynecological morbidity, the rejuvenation of the patient population, and the lack of a single algorithm for rehabilitation measures. On the one hand, effective treatment reduces symptoms, guarantees quality of life, on the other hand, mastopathy is a risk factor for the development of a malignant tumor in the future. Therefore, timely correction of dysplasia can be considered as a variant of primary prevention of breast cancer. The choice of an adequate tactic to manage such patients from the existing variety of dosage forms is the key to the success of treatment.

Key words: mammary glands, uterine myoma, dyshormonal breast diseases, mastopathy, diffuse dysplasia, fibro-cystic disease, progestogens, phytotherapy, transdermal progestogens.

REFERENCES

1. Zahalna teoriia zdorovia ta zdorovia­zberezhennia: kolektyvna monohrafiia, za red. YuD Boichuka. 2017. Kharkiv: Vyd. Rozhko SH: 488.

2. Dudnyk SV, Koshelia II. 2016. Tendentsii stanu zdorovia naselennia Ukrainy. Ukraina. Zdorovia natsii. 4(40):67-77.

3. Shchorichna dopovid pro stan zdorovia naselennia, sanitarno-epidemichnu sytuatsiiu ta rezultaty diialnosti systemy okhorony zdorovia Ukrainy 2017 rik. 2018. MOZ Ukrainy. DU UISD MOZ Ukrainy. Kyiv: MVTs Medinform: 458.

4. Veropotvelyan PN. 2017. Reproduktivnoe zdorove zhenschiny – odna iz vazhneyshih problem gosudarstva. Meditsinskie aspektyi zdorovya zhenschiny 3:34-46.

5. Shurpiak SO, Pyrohova VI. 2018. Reproduktyvne zdorovia i komorbidni stany. Aspekty diahnostyky, likuvannia i reabilitatsii. Lviv, Prostir-M: 224.

6. Hammad AE. 2016. Women and health security. Wld Hlth Statist. Quart. 49(2):74-7.

7. Volff M, fon, Shtute P. 2017. Ginekologicheskaya endokrinologiya i reproduktivnaya meditsina, per.s nem.pod red. EN Andreevoy. M, MEDpress-inform: 512.

8. Radzinskiy VE. 2011. Reproduktivnoe zdorove: Ucheb. posobie. M.: RUDN: 727.

9. Zaporozhan VM ta in. 2013. Akusherstvo ta hinekolohiia: u 4-kh t.: natsionalnyi pidruchnyk. K.: VSV Medytsyna: 1032.

10. Kornatska AH, Tatarchuk TF, Dubenko OD. 2017.Bezplidnist ta dobroiakisni zakhvoriuvannia molochnoi zalozy. Kyiv: 271.

11. Babaeva NA, Ashrafyan LA, Antonova IB, Aleshikova OI, Ivashina SV. 2017. Rol gormonalnyih narusheniy v kantserogeneze opuholey zhenskoy reproduktivnoy sistemyi. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie. 1:76-82.

12. Rozhkova NI, Bozhenko VK, Kaprin AD. 2016. Mammologiya: natsionalnoe rukovodstvo. M, GEOTAR-Media: 496.

13. Saveleva GM, Suhih GT, Serov VN, Manuhin IB, Radzinskiy VE. 2017. Ginekologiya: natsionalnoe rukovodstvo. M, GEOTAR-Media: 1008.

14. Tracking Universal Health Coverage: 2017 Global Monitoring Report. 2017. WHO and the International Bank for Reconstruction and Development: 88.

15. Zhabchenko IA. 2018. Fibrozno-kistozna khvoroba molochnykh zaloz: samostiine zakhvoriuvannia chy viddzerkalennia neharazdiv zhinochoho orhanizmu? Slovo o zdorove http://ozdorovie.com.ua/fibrozno-kistozna-hvoroba-molochnih-zaloz-samostiyne-zahvoryuvannya-chi-viddzerkalennya-negarazdiv-zhinochogo-organizmu/

16. Gilyazutdinov IA. 2016. Neyroendokrinnaya patologiya v ginekologii i akusherstve: Rukovodstvo dlya vrachey. M, MEDpress-inform: 416.

17. Radzinskiy VE. 2017. Meditsina molochnoy zhelezy i ginekologicheskie bolezni. Izd. 2-e, pererab. i dop. M, StatusPraesens: 345.

18. Podzolkova NM, Fadeev IE, PolYotova TN, Sumyatina LV. 2016. Zabolevaniya molochnyh zhelez v ginekologii. M, GEOTAR-Media: 80.

19. Tatarchuk TF, Kalugina LV. 2013. K voprosu o profilaktike i terapii gormonozavisimyih giperproliferativnyih zabolevaniy u zhenschin. Zdorove zhenschiny 7: 51-7.

20. Reznichenko HI, Reznichenko NIu, Potebnia VIu. 2016. Likuvannia dyshormonalnykh dysplazii hrudnykh zaloz. Zdorove zhenshchyny. 3(109): 93-102.

21. Shurpyak SA. 2018. Otsenka effektivnosti differentsirovannoy terapii sochetannoy disgormonalnoy patologii reproduktivnyih organov u zhenschin fertilnogo vozrasta s komorbidnyimi sostoyaniyami. Reproduktivnoe zdorove. Vostochnaya Evropa. 8(4): 534-544.

22. Adamyan LV. 2015. Mioma matki: diagnostika, lechenie i reabilitatsiya: klinicheskie rekomendatsii po vedeniyu bolnyih (proekt). M.: 100.

23. Dobrohotova YuE, Ibragimova DM, Sapryikina LV. 2018. Mioma matki. M, GEOTAR-Media: 96.

24. Yao JP, Hao YZ, Chang Q, Geng CY, Chen Y, Zhao WP, Song Y, Zhou X. 2017. Value of Ultrasonographic Features for Assessing Malignant Potential of Complex Cystic Breast Lesions J Ultrasound Med. 36(4): 699-704. https://doi.org/10.7863/ultra.16.05012; PMid:28109002

25. Carauleanu A, Socolov R, Rugina V, Gabia O, Carauleanu DM, Lupascu IA, Socolov D. 2016. Comparisons between the non-proliferative and proliferative therapy in fibrocystic mastosis. Rev Med Chir Soc Med Nat Iasi. 120(2): 321-7.

26. Zafrakas M, Grimbizis G, Timologou A, Tarlatzis BC. 2018. Endometriosis and ovarian cancer risk: a systematic review of epidemiological studies. Front. Surg. 1: 14. https://doi.org/10.3389/fsurg.2014.00014; PMid:25593938 PMCid:PMC4286968

27. Radzinskiy VE, Ordiyants IM, Maslennikova MN, Pavlova EA, Kardanova VV. 2017. Vozmozhnosti terapii sochetaniya miomyi matki i dobrokachestvennyih displaziy molochnyih zhelez. Reproduktivna endokrinologіya. 4(36): 86-9.

28. Filippov OS. 2008. Dobrokachestvennyie zabolevaniya molochnyih zhelez. M, MEDPress-inform: 112.

29. Klinicheskie rekomendatsii Rossiyskogo obschestva onkomammologov po profilaktike raka molochnoy zhelezyi, differentsialnoy diagnostike, lecheniyu predopuholevyh i dobrokachestvennyh zabolevaniy molochnyh zhelez. 2016. Opuholi zhenskoy reproduktivnoy sistemy 3(12): 43-52.

30. Manuhin IB, Tumilovich LG, Gevorkyan MA, Manuhina EI. 2017. Ginekologicheskaya endokrinologiya: klin. lektsii. M, GEOTAR-Media: 296.

31. Cherenkov VG, Petrov AB, Tverezovskiy SA, Strozhenkov MM. 2014. Ot patogeneza opuholey molochnyih zhelez i ginekologicheskih bolezney k prakticheskomu resheniyu problemyi. Rossiyskiy onkologicheskiy zhurnal. 5: 47-51.

32. Shurpiak SO. 2018. Otsinka komorbidnosti v menedzhmenti patsiientok z dyshormonalnoiu dobroiakisnoiu poiednanoiu proliferatyvnoiu patolohiieiu reproduktyvnykh orhaniv. Zbirnyk naukovykh prats Asotsiatsii akusheriv-ginekologiv Ukrainy 1 (36): 67-72.

33. Pyrohova VI, Shurpiak SO, Malachynska MI. 2016. Dobroiakisni poiednani dyshormonalni proliferatyvni zakhvoriuvannia orhaniv reproduktyvnoi systemy pry dysfunktsii shchytopodibnoi zalozy. Rozrobka kompleksnykh likuvalno-reabilitatsiinykh zakhodiv. Z turbotoiu pro zhinku. 3(69): 56-60.

34. Howard JW, Jones HW, Wentz AC, Burnett LS. 2017. Novak’s textbook of gynecology. Baltimore: Williams & Wilkins: 919.

35. Rosenstock L, Cullen MR. Brodkin C, Redlich C. 2016. Textbook of Clinical Occupational and Environmental Medicine. 3rd edition. Saunders: 1670.

36. Nakaz MOZ Ukrainy vid 30.06.2015 No. 396 Pro zatverdzhennia unifikovanoho klinichnoho protokolu pervynnoi, vtorynnoi (spetsializovanoi), tretynnoi (vysokospetsializovanoi) medychnoi dopomohy «Rak molochnoi zalozy».

37. Radzinskiy VE, Ordiyants IM, Maslennikova MN, Pavlova EA. 2012. Molochnyie zhelezy i ginekologicheskie bolezni: ot obschnosti patogeneticheskih vozzreniy k prakticheskim resheniyam. Vozmozhnosti ozdorovleniya zhenschin s sochetaniem miomyi matki i dobrokachestvennyih displaziy molochnyih zhelez. M.: Redaktsiya zhurnala StatusPraesens: 16.

38. Torshin IYu, Gromova OA, Limanova OA. 2015. Sistematicheskiy analiz sostava i mehanizmov molekulyarnogo vozdeystviya standartizovannyih ekstraktov Vitex Agnus-castus. Trudnyiy patsient 1-2(13): 19-28.

39. Vyisotskaya IV, Letyagin VP. 2017. Farmakologicheskie effektyi i molekulyarnyie mehanizmyi deystviya lechebnogo fitopreparata na osnove Vitex agnus-castus. Opuholi zhenskoy reproduktivnoy sistemy 13(1): 14-19.

40. Vessey M, Yeates D. 2017. Oral contraceptives and benign breast disease: an update of findings in a large cohort study. Contraception 76(6): 418-24.

41. Andreeva EN, Rozhkova NI. 2016. Effektivnost transdermalnogo gelya, soderzhaschego mikronizirovannyiy progesteron, v lechenii fibrozno-kistoznoy mastopatii. Rezultaty rossiyskogo issledovaniya. Akusherstvo i ginekologiya 12: 1-6.

42. Bespalov VG, Negustorov YuF. 2017. Mammograficheskaya plotnost kak kriteriy effektivnosti lecheniya mastopatii i snizheniya riska raka molochnoy zhelezyi. Opuholi zhenskoy reproduktivnoy sistemy 13(2): 33-41.

43. Kravchenko DN, Parokonnaya AA, Nechushkin MI, Nikitina EA, Hakurinova ND. 2018. Rak molochnoy zhelezyi u bolnyih molodogo vozrasta. Osobennosti prognoza i ad'yuvantnoy gormonoterapii (obzor literatury). Opuholi zhenskoy reproduktivnoy sistemy 14(3): 55-63.